AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28887006 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost (0.004%)
Number of subjects: 157
Study 28887006 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.25% for patients aged 2 months to <3 years and 0.5% for patients ≥3 years old)
Number of subjects: 157
Study 28887006 — intervention group
Group type: COMPARATOR
Intervention: Travoprost vs Timolol
Number of subjects: 157
Study 25227967 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial high-dose prednisolone combination therapy using COBRA regimen (methotrexate and sulfasalazine)
Number of subjects: 0
Study 25227967 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-light variation of COBRA combination therapy
Number of subjects: 0
Study 25227967 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate and infliximab combination therapy
Number of subjects: 0
Study 23138523 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconstrained hands
Number of subjects: 0
Study 23138523 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained hands
Number of subjects: 0
Study 21777013 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg/day, uptitrated to 40 mg/day or combined with HCTZ 40/12.5 mg/day or 40/25 mg/day
Number of subjects: 192
Study 20084816 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom training plus reinforcement
Number of subjects: 120
Study 20084816 — intervention group
Group type: COMPARATOR
Intervention: Classroom training only
Number of subjects: 120
Study 20084816 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 120
Study 18046863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 18
Study 15718612 — intervention group
Group type: EXPERIMENTAL
Intervention: PCLX Laryngograph Processor and Nosality digital modules
Number of subjects: 0
Study 11207321 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (1 mg/kg over 1 h)
Number of subjects: 16
Study 11207321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11207321 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14
Number of subjects: 16
Study 9281302 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole daily
Number of subjects: 30
Study 9281302 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine daily
Number of subjects: 30
Study 9281302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7506323 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 40 micrograms
Number of subjects: 12
Study 7506323 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 60 micrograms
Number of subjects: 12
Study 7506323 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 20 micrograms
Number of subjects: 12
Study 7506323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7506323 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS)
Number of subjects: 12
Study 3129273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined insulin and glibenclamide (Euglucon N)
Number of subjects: 68
Study 3129273 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (placebo)
Number of subjects: 68
Study 29795403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg dose of nicotine
Number of subjects: 0
Study 29795403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27988164 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose interscalene block and general anesthesia (SISB/GA)
Number of subjects: 62
Study 27988164 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 62
Study 26699871 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor homozygote genotype of rs7968585 SNP
Number of subjects: 8461
Study 26699871 — intervention group
Group type: COMPARATOR
Intervention: Major homozygote genotype of rs7968585 SNP
Number of subjects: 8461
Study 23886454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane: SS
Number of subjects: 60
Study 23886454 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-propofol: SP
Number of subjects: 60
Study 23886454 — intervention group
Group type: COMPARATOR
Intervention: Propofol-propofol: PP
Number of subjects: 60
Study 21041606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride treatment
Number of subjects: 196
Study 21041606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 196
Study 21041606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and cognitive behavioral therapy
Number of subjects: 196
Study 21041606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 18320371 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm support band
Number of subjects: 29
Study 18320371 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Number of subjects: 29
Study 18320371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 29
Study 16359772 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg i.m.)
Number of subjects: 60
Study 16359772 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolin (3.75 mg i.m.)
Number of subjects: 60
Study 14521759 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + 3PaZ(TH)L(2)VE(AK) + 4PaL(2)V
Number of subjects: 209
Study 14521759 — intervention group
Group type: COMPARATOR
Intervention: 3PaZ(TH)L(2)VE(AK)/4PaL(2)V
Number of subjects: 209
Study 11139917 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial septal pacing
Number of subjects: 36
Study 11139917 — intervention group
Group type: COMPARATOR
Intervention: Conventional right atrial pacing
Number of subjects: 36
Study 11139917 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial multisite pacing
Number of subjects: 36
Study 8799270 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography/combustion/carbon isotope ratio mass spectrometry (GC/C/IRMS) analysis of urinary steroids
Number of subjects: 8
Study 8799270 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography/combustion/carbon isotope ratio mass spectrometry (GC/C/IRMS)
Number of subjects: 8
Study 8799270 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of carbon isotope ratios of urinary androgens
Number of subjects: 8
Study 1361356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg kg‐1)
Number of subjects: 0
Study 1361356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.08 mg kg‐1)
Number of subjects: 0
Study 6487444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 0
Study 6487444 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 6487444 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 30741425 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endovenous ablation
Number of subjects: 0
Study 30741425 — intervention group
Group type: COMPARATOR
Intervention: Deferred endovenous ablation
Number of subjects: 0
Study 29705832 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 W PVP
Number of subjects: 84
Study 29705832 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 W PVP
Number of subjects: 84
Study 26586300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) applied to one side of the face post-surgery.
Number of subjects: 11
Study 26586300 — intervention group
Group type: COMPARATOR
Intervention: Placebo PEMF device applied to the control side of the face post-surgery.
Number of subjects: 11
Study 26586300 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort evaluation using a numerical rating scale for PEMF devices.
Number of subjects: 11
Study 24923345 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 18) - running 15 minutes at medium intensity (65-75% HRmax)
Number of subjects: 55
Study 24923345 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress group (n = 19)
Number of subjects: 55
Study 24923345 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 55
Study 23008295 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate
Number of subjects: 16508
Study 23008295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16508
Study 19952863 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐6/11/16/18 vaccine
Number of subjects: 21480
Study 19952863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21480
Study 17636242 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositories containing 2.5 mg bromocriptine mesthylate with pluronics and bioadhesive agents, once daily for 1 month
Number of subjects: 171
Study 17636242 — intervention group
Group type: COMPARATOR
Intervention: Commercial 2.5 mg bromocriptine mesthylate tablets inserted vaginally, once daily for 1 month
Number of subjects: 171
Study 15642811 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour self-management program
Number of subjects: 214
Study 15642811 — intervention group
Group type: COMPARATOR
Intervention: Tape-recorded health lectures
Number of subjects: 214
Study 15642811 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 214
Study 12146001 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 10 mg/day
Number of subjects: 67
Study 12146001 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 67
Study 12146001 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group (10 mg + 25 mg)
Number of subjects: 67
Study 10413640 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran at 1.2 mg. kg(‐1). h(‐1)
Number of subjects: 432
Study 10413640 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran (various doses)
Number of subjects: 432
Study 10413640 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 432
Study 10413640 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran
Number of subjects: 432
Study 10413640 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran at levels of at least 0.63 mg. kg(‐1). h(‐1)
Number of subjects: 432
Study 7768238 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9% CHO solution
Number of subjects: 7
Study 7768238 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5% CHO solution
Number of subjects: 7
Study 7768238 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 7
Study 2272094 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 19
Study 2272094 — intervention group
Group type: COMPARATOR
Intervention: Cold packs
Number of subjects: 19
Study 7306430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg three times daily and 400 mg at night for 6 days
Number of subjects: 5
Study 7306430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31888709 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored activity and exercise programme delivered using motivational theory, with up to 50 supervised sessions over one year.
Number of subjects: 368
Study 31888709 — intervention group
Group type: COMPARATOR
Intervention: Brief falls prevention assessment (control).
Number of subjects: 368
Study 28009637 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiniti Plus needle guide
Number of subjects: 0
Study 28009637 — intervention group
Group type: COMPARATOR
Intervention: No Infiniti Plus needle guide
Number of subjects: 0
Study 26404039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention combined with breathing relaxation exercise for four weeks
Number of subjects: 89
Study 26404039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 24144703 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO with cooling (34°C for the first 48 to 72 hours)
Number of subjects: 111
Study 24144703 — intervention group
Group type: COMPARATOR
Intervention: Standard ECMO (37°C)
Number of subjects: 111
Study 24144703 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO with cooling
Number of subjects: 111
Study 24144703 — intervention group
Group type: COMPARATOR
Intervention: Standard ECMO
Number of subjects: 111
Study 24144703 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (death, neonatal morbidity, neurodevelopmental and behavioral outcomes)
Number of subjects: 111
Study 21970738 — intervention group
Group type: EXPERIMENTAL
Intervention: Various management approaches suggested for poor responders in assisted conception, specific interventions not detailed.
Number of subjects: 0
Study 21970738 — intervention group
Group type: EXPERIMENTAL
Intervention: Review of current evidence on management of poor responders, specific interventions not detailed.
Number of subjects: 0
Study 19203712 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (0, 15 or 30 mg Zn per day for 6 months)
Number of subjects: 3
Study 19203712 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 mg Zn per day for 6 months)
Number of subjects: 3
Study 17900060 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix (GSK)
Number of subjects: 3
Study 17900060 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix (GSK) and Engerix-B (GSK)
Number of subjects: 3
Study 17900060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta (Sanofi Pasteur) and HB VAX PRO (Sanofi-Pasteur)
Number of subjects: 3
Study 15131531 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 15131531 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy
Number of subjects: 0
Study 11855146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) in combination with corticosteroid (prednisone + danazol)
Number of subjects: 44
Study 11855146 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen alone (prednisone + danazol)
Number of subjects: 44
Study 9771080 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005% xalathane solution)
Number of subjects: 0
Study 9771080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of latanoprost with pilocarpine + timolol
Number of subjects: 0
Study 7930743 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (10 mg/kg over 3 days) plus mefloquine (25 mg/kg)
Number of subjects: 652
Study 7930743 — intervention group
Group type: COMPARATOR
Intervention: High-dose mefloquine alone
Number of subjects: 652
Study 7930743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine on day 2 of treatment
Number of subjects: 652
Study 3280484 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-zero sphygmomanometer
Number of subjects: 66
Study 3280484 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer
Number of subjects: 66
Study 29908345 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions to failure (RFG, n=17)
Number of subjects: 52
Study 29908345 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions not to failure (NFG, n=20)
Number of subjects: 52
Study 29908345 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions not to failure with total volume equalized to that in the RFG (ENFG, n=15)
Number of subjects: 52
Study 29908345 — intervention group
Group type: COMPARATOR
Intervention: All CT groups (RFG, NFG, ENFG)
Number of subjects: 52
Study 27745629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair follicle-containing punch grafts
Number of subjects: 12
Study 27745629 — intervention group
Group type: COMPARATOR
Intervention: Nonhairy punch grafts (Control)
Number of subjects: 12
Study 24525910 — intervention group
Group type: COMPARATOR
Intervention: TCZ + PBO
Number of subjects: 63
Study 24525910 — intervention group
Group type: COMPARATOR
Intervention: TCZ + MTX
Number of subjects: 63
Study 22428914 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Glucobay® 100 mg tablet)
Number of subjects: 33
Study 22428914 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (generic acarbose 100 mg tablet)
Number of subjects: 33
Study 22428914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19573960 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Diet Plus (n-3 polyunsaturated fatty acid-enriched diet)
Number of subjects: 65
Study 19573960 — intervention group
Group type: COMPARATOR
Intervention: Jevity (enteral diet intended for elderly)
Number of subjects: 65
Study 18942249 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Lumen Tube (SLT)
Number of subjects: 30
Study 18942249 — intervention group
Group type: COMPARATOR
Intervention: Double Lumen Tube (DLT)
Number of subjects: 30
Study 17937364 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 13
Study 17937364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12722964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg daily
Number of subjects: 245
Study 11097979 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 61
Study 11097979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9113472 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack bar containing uncooked cornstarch (bar 1)
Number of subjects: 79
Study 9113472 — intervention group
Group type: COMPARATOR
Intervention: Control bar (bar 2)
Number of subjects: 79
Study 8469785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg three times daily for 12 weeks
Number of subjects: 25
Study 8469785 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 4035629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute hydrochloric acid (0.001 N)
Number of subjects: 18
Study 4035629 — intervention group
Group type: EXPERIMENTAL
Intervention: More concentrated hydrochloric acid (0.01 N)
Number of subjects: 18
Study 4035629 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid drink (0.001 N)
Number of subjects: 18
Study 4035629 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux associated with acid drink response
Number of subjects: 18
Study 30204981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and pharyngoplasty
Number of subjects: 603
Study 30204981 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy alone
Number of subjects: 603
Study 26850676 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (orally inhaled salbutamol)
Number of subjects: 24
Study 26850676 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (orally inhaled salbutamol)
Number of subjects: 24
Study 26850676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 24902481 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (SAMS)
Number of subjects: 211
Study 24902481 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 211
Study 22382087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstandard RapidArc (RA)
Number of subjects: 27
Study 22382087 — intervention group
Group type: COMPARATOR
Intervention: Standard RapidArc (RA)
Number of subjects: 27
Study 22382087 — intervention group
Group type: COMPARATOR
Intervention: HDR‐BRT
Number of subjects: 27
Study 22382087 — intervention group
Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 27
Study 22382087 — intervention group
Group type: COMPARATOR
Intervention: Integral doses
Number of subjects: 27
Study 21102969 — intervention group
Group type: COMPARATOR
Intervention: OM-ER 15 mg
Number of subjects: 35
Study 21102969 — intervention group
Group type: COMPARATOR
Intervention: OM-ER 30 mg
Number of subjects: 35
Study 18319295 — intervention group
Group type: EXPERIMENTAL
Intervention: International Program on Chemical Safety Poison Severity Score (IPCS PSS)
Number of subjects: 1365
Study 18319295 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (GCS)
Number of subjects: 1365
Study 18319295 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (GCS) for dimethoate poisoning
Number of subjects: 1365
Study 18319295 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Score (GCS) for fenthion poisoning
Number of subjects: 1365
Study 15952100 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU rIFN‐beta‐1a (group A)
Number of subjects: 91
Study 15952100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MIU rIFN‐beta‐1a (group B)
Number of subjects: 91
Study 15952100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 91
Study 12600910 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic guidance with standard sampling (3 to 6 samples per patient)
Number of subjects: 49
Study 12600910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardioscopy guidance with standard sampling (4 to 6 samples per patient)
Number of subjects: 49
Study 12600910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardioscopy guidance with extensive sampling (18 to 20 samples per patient)
Number of subjects: 49
Study 10224679 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy laser radiation treatment in addition to routine antibiotic therapy
Number of subjects: 68
Study 10224679 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotic therapy
Number of subjects: 68
Study 8903538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac amyloidosis patients
Number of subjects: 30
Study 8903538 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 2004544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 125 mg twice daily
Number of subjects: 672
Study 2004544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily
Number of subjects: 672
Study 2004544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 672
Study 6572041 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial forward relocation of the center of mass of the head
Number of subjects: 0
Study 30713722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 394